The FDA and "privatization"--the drug approval process.
作者信息
Rutherford E M
机构信息
Procter & Gamble Company, Cincinnati, Ohio, USA.
出版信息
Food Drug Law J. 1995;50 Spec:203-25.
PMID:10343044
Abstract
摘要
相似文献
1
The FDA and "privatization"--the drug approval process.
Food Drug Law J. 1995;50 Spec:203-25.
2
Drug safety reform at the FDA--pendulum swing or systematic improvement?
N Engl J Med. 2007 Apr 26;356(17):1700-2. doi: 10.1056/NEJMp078057. Epub 2007 Apr 13.
3
The impact of FDA reform.
Med Device Technol. 2003 Apr;14(3):36-7.
4
A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
Suffolk Univ Law Rev. 2003;36(3):787-819.
5
Lawsuits anticipated on generic biologicals front.
Nat Biotechnol. 2003 Jul;21(7):721-2. doi: 10.1038/nbt0703-721.
6
Pharmaceuticals and medical devices: FDA oversight.
Issue Brief Health Policy Track Serv. 2012 Jan 3:1-86.
7
Recent developments help the defense of drug companies in 10b-5 cases.
Food Drug Law J. 1996;51(3):345-53.
8
Perspectives. Approval process a moving target in FDA reform hearings.
Faulkner Grays Med Health. 1996 Feb 19;50(8):suppl 1-4.
9
The application of the patent laws to the drug approval process.
Food Drug Law J. 1997;52(4):345-55.
10
Pros and cons of off-label promotion investigations and prosecutions.
Food Drug Law J. 2006;61(3):577-83.
引用本文的文献
1
Facilitating a More Efficient Commercial Review Process for Pediatric Drugs and Biologics.
Diseases. 2017 Dec 22;6(1):2. doi: 10.3390/diseases6010002.
Zotero 插件